Background: The CRASH-2 trial, published in 2010, showed a survival benefit for patients with traumatic hemorrhage who received TXA compared to placebo. TXA has become standard practice in many settings as a result of this data. However, patients with significant …
Background: Convalescent plasma therapy (CPT) is not a novel treatment modality. It has been used in other illnesses such as SARS, MERS, and Ebola with variable results. The theory behind CPT is to take antibody rich blood from patients who …
Background: Previous evidence has found that oseltamivir reduces median time to alleviation of influenza symptoms over placebo by about 1 day. The benefits were greater when treatment was initiated within 24 to 48 hours of symptoms onset. Many previous trials …
Background: Though it’s been stated numerous times on this blog, it bears repeating: the pillars of sepsis care remain early identification of sepsis, early appropriate empiric antibiotics, source control, and supportive care. The focus should be on getting the basics …
Background: There are three randomized clinical trials now published on remdesivir in the treatment of COVID-19 pneumonia (RCT 1, RCT 2, & RCT 3). The 1st trial, performed in China, was terminated early due the lack of patients to enroll …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
